Quarterly report pursuant to Section 13 or 15(d)

7. Stockholders' Equity (Details Narrative)

v3.7.0.1
7. Stockholders' Equity (Details Narrative) - $ / shares
 6 Months Ended
Jun. 30, 2017
Dec. 31, 2016
Debt and Equity Financing [Member]    
Warrants outstanding 3,522,225 3,522,225
Warrants weighted average exercise price $ 4.30  
Pharmsynthez [Member]    
Convertible note converted, shares issued 125,397  
Series B Preferred Stock [Member]    
Preferred stock converted, shares converted 185,000  
Common Stock [Member]    
Preferred stock converted, common shares issued 185,000